Allscripts Healthcare Solutions Inc (NASDAQ:MDRX) CEO Paul Black purchased 24,765 shares of the company’s stock in a transaction on Wednesday, December 12th. The stock was purchased at an average cost of $10.10 per share, for a total transaction of $250,126.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.
NASDAQ:MDRX opened at $10.39 on Friday. The company has a debt-to-equity ratio of 1.61, a quick ratio of 0.94 and a current ratio of 0.94. The stock has a market capitalization of $1.82 billion, a P/E ratio of 20.37, a P/E/G ratio of 1.47 and a beta of 1.28. Allscripts Healthcare Solutions Inc has a 52-week low of $9.24 and a 52-week high of $16.13.
Allscripts Healthcare Solutions (NASDAQ:MDRX) last released its earnings results on Thursday, November 1st. The software maker reported $0.13 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.01). The company had revenue of $536.00 million during the quarter, compared to analyst estimates of $546.09 million. Allscripts Healthcare Solutions had a negative net margin of 0.25% and a positive return on equity of 8.25%. Allscripts Healthcare Solutions’s revenue was up 18.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.15 EPS. On average, analysts anticipate that Allscripts Healthcare Solutions Inc will post 0.54 earnings per share for the current year.
Several analysts have issued reports on MDRX shares. TheStreet raised Allscripts Healthcare Solutions from a “c+” rating to a “b-” rating in a research note on Thursday, September 6th. Citigroup dropped their price target on Allscripts Healthcare Solutions from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday, November 2nd. Bank of America dropped their price target on Allscripts Healthcare Solutions from $16.50 to $15.00 and set a “buy” rating on the stock in a research note on Friday, November 2nd. Zacks Investment Research raised Allscripts Healthcare Solutions from a “sell” rating to a “hold” rating in a research note on Thursday, November 15th. Finally, Argus downgraded Allscripts Healthcare Solutions from a “buy” rating to a “hold” rating in a research report on Wednesday, November 14th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $15.51.
ILLEGAL ACTIVITY WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The original version of this news story can be read at https://www.com-unik.info/2018/12/16/allscripts-healthcare-solutions-inc-mdrx-ceo-acquires-250126-50-in-stock.html.
About Allscripts Healthcare Solutions
Allscripts Healthcare Solutions, Inc provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records, connectivity, private cloud hosting, outsourcing, analytics, patient engagement, clinical decision support, and population health management solutions.
See Also: Conference Calls
Receive News & Ratings for Allscripts Healthcare Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allscripts Healthcare Solutions and related companies with MarketBeat.com's FREE daily email newsletter.